Physician profile
Horacio E Adrogue
NPI 1508958000
$122,482.42
in general payments reported to CMS, 2019-2025
27 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,752 · 2020: $12K · 2021: $16K · 2022: $14K · 2023: $5,065 · 2024: $48K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $13K · Travel and Lodging: $5,753 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,600 · Food and Beverage: $5,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,500.00 |
| Consulting Fee | $13,225.00 |
| Travel and Lodging | $5,753.05 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,600.00 |
| Food and Beverage | $5,011.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $60,425.25 | 2023-2025 | Filspari |
| Alexion Pharmaceuticals, INC. | $25,380.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $24,273.33 | 2019-2024 | Farxiga, Lokelma |
| Mallinckrodt Enterprises LLC | $4,150.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,379.20 | 2021-2022 | |
| Vifor Pharma, INC. | $2,174.94 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $673.28 | 2025 | Tarpeyo |
| Gilead Sciences, INC. | $296.58 | 2019-2022 | |
| Glaxosmithkline, LLC. | $275.78 | 2022-2023 | Jesduvroq |
| Fresenius USA Marketing, INC. | $269.39 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $240.94 | 2019-2025 | Jynarque |
| Amgen INC. | $237.68 | 2022-2024 | Krystexxa, Tavneos, Aranesp |
| Akebia Therapeutics INC | $225.03 | 2020-2024 | Vafseo |
| Novo Nordisk INC | $203.16 | 2024-2025 | Rivfloza |
| Aurinia Pharma U.S., INC. | $190.75 | 2021-2024 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $167.55 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $166.65 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $155.00 | 2025 | Empaveli |
| Veloxis Pharmaceuticals, INC. | $150.79 | 2019 | |
| Eisai INC. | $117.26 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.80 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $108.81 | 2019-2023 | Onpattro |
| Sanofi-Aventis U.S. LLC | $42.71 | 2023 | |
| Opko Pharmaceuticals, LLC | $19.67 | 2023 | Rayaldee |
| Genzyme Corporation | $16.84 | 2019 | |
| Merck Sharp & Dohme LLC | $13.44 | 2019 | |
| Allergan, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Horacio Adrogue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.